Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis

This is a preview and has not been published.

Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis

Authors

  • Figen Öztürk Ergür Atatürk Sanatoryum Training and Research Hospital, Department of Pulmonary Medicine, Ankara, Turkey
  • Ayperi Öztürk Atatürk Sanatoryum Training and Research Hospital, Department of Pulmonary Medicine, Ankara, Turkey
  • Barış Akgül Atatürk Sanatoryum Training and Research Hospital, Department of Pulmonary Medicine, Ankara, Turkey
  • Aydın Yılmaz Atatürk Sanatoryum Training and Research Hospital, Department of Pulmonary Medicine, Ankara, Turkey
  • Ömür Güngör Adana City Training and Research Hospital, Department of Pulmonary Medicine, Adana, Türkiye

Keywords:

Hypersensitivity Pneumonitis; fibrosis; emphysema; lung function; dual pathology; radiological phenotype

Abstract

Background and aim: Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease with heterogeneous presentations. In some patients, radiological coexistence of emphysema and fibrosis creates a distinct functional phenotype that complicates disease progression and management. To evaluate the functional impact of combined emphysema and fibrosis in HP patients and to identify clinical predictors associated with this dual pathology.

Methods: We retrospectively analyzed 215 patients diagnosed with HP between 2010 and 2023. Demographic data, exposure history, radiological findings (HRCT), and pulmonary function parameters (FVC, DLCO, FEV₁) were collected. Patients were classified into three groups: fibrotic HP, non-fibrotic HP, and combined emphysema with fibrosis (CE-HP). Statistical analyses were performed using SPSS v22.0.

Results: Of the 215 patients, 68 (31.6%) had fibrotic HP and 42 (19.5%) presented with CE-HP. Patients with CE-HP were significantly older (mean 66.2 ± 9.1 years) and more often male and smokers (p < 0.05). FVC and DLCO values were lower in CE-HP compared with non-fibrotic and fibrotic groups. A moderate negative correlation was found between extent of emphysema and DLCO (r = −0.56, p < 0.001). In multivariate analysis, age > 65 years, male gender, and smoking history were independent predictors of CE-HP development.

Conclusions: The coexistence of emphysema and fibrosis in HP represents a distinct clinical phenotype with significant functional impairment. Recognition of this dual pathology is crucial for accurate prognostication and individualized management strategies.

 

References

1. Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia. Where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196(6):690-9. doi: 10.1164/rccm.201608-1675PP

2. Vasakova M, Morell F, Walsh S, Leslie K, Raghu G. Hypersensitivity pneumonitis: perspectives in diagnosis and management. Am J Respir Crit Care Med. 2017;196(6):680-9. doi: 10.1164/rccm.201611-2201PP

3. Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2020;202(3):e36-69. doi: 10.1164/rccm.202005-2032ST

4. Fernández Pérez ER, Travis WD, Lynch DA, Brown KK, Dengel JL, Hauber HP, et al. Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med. 2018;197(6):688-97. doi: 10.1164/rccm.201708-1675PP

5. Hanak V, Golbin JM, Ryu JH. Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc. 2007;82(7):812-6. doi: 10.4065/82.7.812

6. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, et al. Identification of diagnostic criteria for chronic hypersensitivity pneumonitis: an international modified Delphi survey. Am J Respir Crit Care Med. 2018;197(8):1036-44. doi: 10.1164/rccm.201710-1986OC

7. Uzun O, Adıguzel Gundogdu B, Sullu Y, Topcu Erturk K, Kement S, Selen Ala Cıtlak F. Hypersensitivity pneumonitis in Türkiye: an underrecognized pulmonary disorder. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(2):15884. doi: 10.36141/svdld.v42i2.15884

8. Morell F, Villar A, Montero MA, Muñoz X, Colby TV, Pipvath S, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med. 2013;1(9):685-94. doi: 10.1016/S2213-2600(13)70191-7

9. Okazaki Y, Kurashima K, Nakano Y, Taniguchi H, Kondoh Y, Ogura T, et al. Changes in computed tomography findings in chronic hypersensitivity pneumonitis: relationship with pulmonary function and prognosis. Respir Investig. 2016;54(5):350-7. doi: 10.1016/j.resinv.2016.03.002

10. Ohtani Y, Saiki S, Sumi Y, Inase N, Miyake S, Costabel U, et al. Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol. 2003;90(6):604-10. doi: 10.1016/S1081-1206(10)61863-7

11. Koyuncu A, Sarı G, Şimşek C. Evaluation of cases with hypersensitivity pneumonia: 10 year analysis. Clin Respir J. 2023;17(4):329-38. doi: 10.1111/crj.13598

12. Adegunsoye A, Oldham JM, Chung JH, Montner SM, Lee C, Witt LJ, et al. Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest. 2018;153(2):349-60. doi: 10.1016/j.chest.2017.09.026

13. Spagnolo P, Rossi G, Cavazza A, Bonifazi M, Paladini I, Bonella F, et al. Hypersensitivity pneumonitis: a comprehensive review. J Investig Allergol Clin Immunol. 2015;25(4):237-50.

14. De Sadeleer LJ, Hermans F, De Dycker E, Yserbyt J, Verschakelen JA, Verbeken EK, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med. 2018;8(1):14. doi: 10.3390/jcm8010014

15. Fernández Pérez ER, Swigris JJ, Forssén AV, Tourin O, Solomon JJ, Huie TJ, et al. Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest. 2013;144(5):1644-51. doi: 10.1378/chest.12-2685

16. Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180076. doi: 10.1183/16000617.0076-2018

17. Jacob J, Bartholmai BJ, Rajagopalan S, Kokosi M, Nair A, Karwoski R, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J. 2017;49(1):1601011. doi: 10.1183/13993003.01011-2016

18. Tokura S, Okamoto T, Tsuchiya T, Shono A, Ideura G, Sakamoto O, et al. Outcome of chronic hypersensitivity pneumonitis: importance of bronchiolocentric fibrosis on histology. Respirology. 2017;22(5):965-72. [Epub ahead of print; not indexed in PubMed].

19. Falfán-Valencia R, Camarena Á, Juárez A, Becerril C, Montaño M, Cisneros J, et al. Genetic susceptibility to hypersensitivity pneumonitis: TNF and IL-6 promoter polymorphisms. Eur Respir J. 2004;23(5):821-5. doi: 10.1183/09031936.04.00078304

20. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, et al. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017;5(8):639-47. doi: 10.1016/S2213-2600(17)30216-3

21. Fernández Pérez ER, Kong AM, Raimundo K, Koelsch TL, Kulkarni R, Cole AL. Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc. 2018;15(4):460-9. doi: 10.1513/AnnalsATS.201704-288OC

22. Jacobs RL, Andrews CP, Coalson JJ. Hypersensitivity pneumonitis: beyond classic occupational disease-changing concepts of diagnosis and management. Ann Allergy Asthma Immunol. 2005;95(2):115-28. doi: 10.1016/S1081-1206(10)61200-8

23. Takemura T, Akashi T, Kamiya H, Ikushima S, Ando T, Oritsu M, et al. Pathological differentiation of chronic hypersensitivity pneumonitis from idiopathic pulmonary fibrosis/usual interstitial pneumonia. Histopathology. 2012;61(6):1026-35. doi: 10.1111/j.1365-2559.2012.04322.x

24. Ozgun Niksarlioglu EY, Uysal MA, Seyhan EC, Kıyık M, Çetinkaya E. Hypersensitivity pneumonitis in Covid-19: mortality, risk factors, and clinical outcomes from a 30-case observational study. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(1):16163. doi: 10.36141/svdld.v42i1.16163

25. Mammadova A, Yalçınkaya Z, Yılmaz Demirci N, Türktaş H. The prognostic value of peripheral hematological biomarkers in patients with hypersensitivity pneumonitis: a single-center retrospective study. Sarcoidosis Vasc Diffuse Lung Dis. 2025;42(4):17291. doi: 10.36141/svdld.v42i4.17291

26. Mooney JJ, Elicker BM, Urbania TH, Agarwal MR, Ryerson CJ, Nguyen MLT, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest. 2013;144(2):586-92. doi: 10.1378/chest.12-2623

27. Ojanguren I, Morell F, Ramón MA, Villar A, Romero C, Cruz MJ, et al. Long-term outcomes in chronic hypersensitivity pneumonitis. Allergy. 2019;74(5):944-52. doi: 10.1111/all.13692

Downloads

How to Cite

1.
Öztürk Ergür F, Öztürk A, Akgül B, Yılmaz A, Güngör Ömür. Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2026 May 31];43(2):18084. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/18084

Issue

Section

Original Articles: Clinical Research

How to Cite

1.
Öztürk Ergür F, Öztürk A, Akgül B, Yılmaz A, Güngör Ömür. Dual pathology, dual burden: Functional impact of emphysema and fibrosis in Hypersensitivity Pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2026 May 31];43(2):18084. Available from: https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/18084